4 research outputs found
Descriptive statistics of <i>ABCB7</i> expression levels in CD34<sup>+</sup> cells according to FAB group, in CD34<sup>+</sup> cells according to percentage of bone marrow ring sideroblasts, and in cultured erythroblasts at day 7.
<p>Descriptive statistics of <i>ABCB7</i> expression levels in CD34<sup>+</sup> cells according to FAB group, in CD34<sup>+</sup> cells according to percentage of bone marrow ring sideroblasts, and in cultured erythroblasts at day 7.</p
Confirmation of the microarray data for the <i>ABCB7</i> gene using real-time quantitative PCR.
<p>Confirmation of the microarray data for the <i>ABCB7</i> gene using real-time quantitative PCR.</p
Additional file 1: Figure S1. of Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
Study populations in the MDS-003 and MDS-004 studies. Gray shaded boxes: age groups in the present analysis. LEN, lenalidomide. (DOCX 39Â kb
Additional file 2: Table S1. of Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
Cumulative rates of AML progression by age group in lenalidomide-treated patients. AML, acute myeloid leukemia; MDS, myelodysplastic syndromes. (DOCX 14Â kb